AKBA logo

Akebia Therapeutics, Inc.

AKBA

AKBA: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

more

Show AKBA Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of AKBA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by AKBA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $310,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Apr 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $300,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $270,000 Jan 20, 2022 Issue: None
  • $300,000 Oct 20, 2021 Issue: None
  • $400,000 Jul 20, 2021 Issue: None
  • $340,000 Apr 20, 2021 Issue: None
  • $310,000 Jan 21, 2021 Issue: None
  • $340,000 Oct 20, 2020 Issue: None
  • $510,000 Jul 20, 2020 Issue: None
  • $450,000 Apr 20, 2020 Issue: None
  • $300,000 Jan 21, 2020 Issue: None
  • $420,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues
  • $650,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $440,000 Apr 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $140,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
  • $90,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
U.S. Patents

New patents grants

  • Patent Title: Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Aug. 01, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 04, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid Dec. 13, 2022
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 30, 2022
  • Patent Title: Compositions and methods for treating anemia May. 10, 2022
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Mar. 08, 2022
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 20, 2021
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Aug. 11, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 04, 2020
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Mar. 24, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jun. 18, 2019
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Apr. 02, 2019
  • Patent Title: Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jun. 05, 2018
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Oct. 03, 2017
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 11, 2017
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Mar. 21, 2017
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Sep. 29, 2015
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 27, 2015
  • Patent Title: Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer Oct. 21, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and method of use May. 13, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 03, 2013
  • Patent Title: Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase Aug. 20, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 01, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 04, 2012
  • Patent Title: N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones Mar. 13, 2012
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of AKBA in WallStreetBets Daily Discussion

AKBA News

Recent insights relating to AKBA

CNBC Recommendations

Recent picks made for AKBA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AKBA

Corporate Flights

Flights by private jets registered to AKBA